In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. All scholarly work records and full-texts stored in Manchester eScholar were migrated to the new system prior to this transition. From August 2016 the University’s research outputs will be available to view and download via the new Research Portal. Until then the old eScholar content WILL BE TEMPORARILY available to search and browse via this archive.

Hormonal-Regulation of Circulating Insulin-Like Growth Factor-Binding Protein-Phosphorylation Status

Westwood, M; Gibson, J M; Williams, A C; Clayton, P E; Hamberg, O; Flyvbjerg, A; White, A

Journal of Clinical Endocrinology & Metabolism. 1995;80(12):3520-3527.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally

Abstract

Insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) normally circulates as a single, highly phosphorylated species. However, IGFBP-1 phosphorylation status can be altered, such as in pregnancy where non- and lesser phosphorylated isoforms are also present. We have examined how hormonal regulators of circulating IGFBP-1 influence its phosphorylation status and, hence, its ability to modulate IGF activity. In response to insulin-induced hypoglycemia (0.2 U/kg, iv), an increase in the highly phosphorylated isoform was observed after 5 h [16 (range, 11.5-35.5) to 77 (range, 63-250) mu g/L; 4.8-fold increase; P = 0.009], but no non- or lesser phosphorylated variants could be detected. Glucagon (1 mg, sc), increased IGFBP-1 from 27 (range, 13-36.5) to 112 (range, 100.5-129) mu g/L (4.1-fold increase; P = 0.009) after 90 min despite preceding insulin concentrations of more than 500 pmol/L, but again the IGFBP-1 remained in the highly phosphorylated form. Regulation of IGFBP-1 phosphorylation by sex steroids was studied by comparing women receiving a combined oral contraceptive with women on no medication. Although plasma IGFBP-1 levels were significantly elevated in the treatment group [120 (range, 97.5-237.5) vs. 52 (range, 38-70) mu g/L; P < 0.004], there was no difference in the form of IGFBP-1 present. The acute effect of somatostatin (500 mu g/h) on IGFBP-1 phosphorylation status was also studied. Somatostatin only increased the phosphoform characteristic of normal subjects; the appearance of non- or lesser phosphorylated variants was not induced. The effect of rhIGF-I (80 or 120 mu g, sc) on plasma IGFBP-1 was studied in three subjects with Laron's syndrome. A transient increase in the highly phosphorylated isoform of IGFBP-1 was noted; there was no rise in the non- and lesser phosphorylated isoforms also found in the plasma of Laron's syndrome subjects. These data suggest that only the highly phosphorylated species of IGFBP-1 is under hormonal control; regulation of the non- and lesser phosphorylated variants remains to be determined.

Bibliographic metadata

Type of resource:
Content type:
Published date:
ISSN:
Volume:
80
Issue:
12
Start page:
3520
End page:
3527
Total:
8
Pagination:
3520-3527
ISI Accession Number:
ISI:A1995TJ04900023
Related website(s):
  • Related website <Go to ISI>://A1995TJ04900023
Access state:
Active

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:151213
Created by:
Gibson, Martin
Created:
15th January, 2012, 15:04:02
Last modified by:
Gibson, Martin
Last modified:
1st February, 2013, 19:46:08

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.